Irinotecan Hydrochloride Injection
Product Images NDC 70700-170

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 70700-170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2ml-carton (2ml Carton)

This text is a description of a pharmaceutical product named Irinotecan hydrochloride trihydrate. Each mL contains 20mg of irinotecan hydrochloride trihydrate, 45mg of sorbitol, 0.9mg of lactic acid, and water for injection. It is a sterile, aqueous solution and it is available in a single-dose vial. It is a cytotoxic agent and must be diluted before use. The dosage and use instructions are available in the accompanying prescribing information. The manufacturer is Xiromed LLC, and it should be protected from light and freezing. Unused portions should be discarded.*

FDA Label Image

5ml-carton (5ml Carton)

This is a description of a sterile aqueous solution of Irinotecan hydrochloride trihydrate, which must be diluted before use and used intravenously. It is intended for use as a cytotoxic agent, and it comes in a 5 mL single dose vial. It is important to discard any unused portion, and to store it at a temperature between 20-25°C (68-77°F), protected from both light and freezing. The product is manufactured by Xiromed LLC and is intended for intravenous use only, and it was manufactured in India.*

FDA Label Image

Irinotecan-container-label-100mg (Irinotecan Container Label 100mg)

FDA Label Image

Irinotecan-container-label-40mg (Irinotecan Container Label 40mg)

FDA Label Image

Irinotecan Spl Figure 1

FDA Label Image

Irinotecan Spl Figure 2

FDA Label Image

Irinotecan-spl-figure-3 (Irinotecan Spl Figure 3)

FDA Label Image

Irinotecan-spl-figure-4 (Irinotecan Spl Figure 4)

This text appears to be reporting some data related to a medical study or trial. The study involves an intervention called "Innotecan 5-FU," and the text reports the number of participants in the study (127 or 129). There is also a mention of a "median follow-up" of 15 months. The last line appears to be reporting a median value, possibly related to the duration of the study or the outcomes being measured, although the specific context is unclear from the provided text.*

FDA Label Image

Irinotecan-spl-structure (Irinotecan Spl Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.